TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20837952

Group type: EXPERIMENTAL
Intervention: Regimen 1A: Irinotecan 20 mg/m(2)/d intravenously for 5 days at weeks 1, 2, 4, and 5 with vincristine 1.5 mg/m(2) on day 1 of weeks 1, 2, 4, and 5
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Regimen 1B: Irinotecan 50 mg/m(2)/d intravenously for 5 days at weeks 1 and 4 with vincristine as in regimen 1A
Number of subjects: 92
Study: 18443034

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 500 mg
Number of subjects: 12
Study: 15983224

Group type: EXPERIMENTAL
Intervention: GLP-1 (0.8 pmol · kg‐1 · min‐1 from ‐30 to 240 min)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg intravenously from ‐30 to ‐15 min) with GLP-1
Number of subjects: 9

Group type: COMPARATOR
Intervention: GLP-1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Erythromycin with GLP-1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 9
Study: 12669484

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 0
Study: 11136881

Group type: EXPERIMENTAL
Intervention: i.m. gold (n=114)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: methotrexate (MTX; n=118)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: hydroxychloroquine (HCQ; n=120)
Number of subjects: 419

Group type: COMPARATOR
Intervention: NSAID only (n=67)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: SAARDs (combined; n=352)
Number of subjects: 419
Study: 9340928

Group type: EXPERIMENTAL
Intervention: Diffractive MIOL (3M, type 815LE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Refractive MIOL (Allergan, type Array SSM 26NB)
Number of subjects: 0
Study: 1440118

Group type: EXPERIMENTAL
Intervention: 10 mL 0.12% chlorhexidine gluconate (Peridex, Procter & Gamble)
Number of subjects: 76

Group type: COMPARATOR
Intervention: 10 mL placebo
Number of subjects: 76
Study: 3818052

Group type: EXPERIMENTAL
Intervention: Sliding screw plate
Number of subjects: 104

Group type: COMPARATOR
Intervention: Four AO cancellous bone screws
Number of subjects: 104
Study: 31403610

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g·d for 7 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Calcium lactate supplementation (placebo)
Number of subjects: 14
Study: 29056249

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: COMPARATOR
Intervention: Rituximab and Placebo
Number of subjects: 23
Study: 26888096

Group type: EXPERIMENTAL
Intervention: Para (1000 mg paracetamol)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Para‐Caf (1000 mg paracetamol/130 mg caffeine)
Number of subjects: 40
Study: 23856296

Group type: EXPERIMENTAL
Intervention: AZD3480 50 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22223618

Group type: EXPERIMENTAL
Intervention: Reboxetine (NARI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Citalopram (SSRI)
Number of subjects: 0
Study: 20494234

Group type: EXPERIMENTAL
Intervention: Physical activity promotion programs targeting older adults (aged >=60 years)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Physical activity promotion programs targeting obese individuals
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Physical activity promotion programs targeting current cigarette smokers
Number of subjects: 576
Study: 18580179

Group type: EXPERIMENTAL
Intervention: Delta‐tetrahydrocannabinol‐standardized cannabis extract
Number of subjects: 18

Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 18
Study: 15752944

Group type: EXPERIMENTAL
Intervention: ACEi (Angiotensin-Converting Enzyme Inhibitor)
Number of subjects: 23

Group type: COMPARATOR
Intervention: ARB (Angiotensin II Receptor Blocker)
Number of subjects: 23
Study: 12834674

Group type: EXPERIMENTAL
Intervention: Rigid gas permeable (RGP) contact lenses
Number of subjects: 428

Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 428
Study: 9436721

Group type: EXPERIMENTAL
Intervention: 250 Dysport units
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 500 Dysport units
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 1000 Dysport units
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 7645935

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Ultrasound (sonography)
Number of subjects: 73
Study: 2971131

Group type: EXPERIMENTAL
Intervention: 100 micrograms hANP (Bissendorf peptide)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29445269

Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin oral controlled absorption system (OCAS)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin OCAS
Number of subjects: 81
Study: 27218270

Group type: EXPERIMENTAL
Intervention: PCSK9 R46L carriers
Number of subjects: 103083

Group type: COMPARATOR
Intervention: PCSK9 R46L noncarriers
Number of subjects: 103083

Group type: EXPERIMENTAL
Intervention: PCSK9 R46L heterozygotes
Number of subjects: 103083
Study: 24803474

Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 1223

Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 1223

Group type: EXPERIMENTAL
Intervention: Glutamine + Antioxidants
Number of subjects: 1223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1223
Study: 23470848

Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (QIV)
Number of subjects: 2738

Group type: COMPARATOR
Intervention: Trivalent influenza vaccines (TIV)
Number of subjects: 2738
Study: 21707573

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate shampoo 0.05% (CP) twice weekly alternating with ketoconazole shampoo 2% (KC) twice weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate shampoo 0.05% (CP) twice weekly (C2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate shampoo 0.05% (CP) four times weekly alternating with ketoconazole shampoo 2% (KC) twice weekly (C4+K2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ketoconazole shampoo 2% (KC) twice weekly (K2)
Number of subjects: 0
Study: 20151523

Group type: EXPERIMENTAL
Intervention: Caffeine intake during pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recommendations for anesthesiologists and obstetrician-gynecologists
Number of subjects: 0
Study: 16721394

Group type: EXPERIMENTAL
Intervention: Probiotic (Bifidobacterium animalis subsp lactis BB-12) at 10(11) CFU/day
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Probiotic (Bifidobacterium animalis subsp lactis BB-12)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Probiotic (Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-431)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 15569389

Group type: EXPERIMENTAL
Intervention: Digital lectures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Live lectures
Number of subjects: 0
Study: 11326768

Group type: EXPERIMENTAL
Intervention: C‐CARE plus CAST
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: C‐CARE only
Number of subjects: 341

Group type: COMPARATOR
Intervention: Intervention as usual
Number of subjects: 341
Study: 9155956

Group type: EXPERIMENTAL
Intervention: Botulinum A toxin (Dysport) - 120 mU injected into six different sites on one palm
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sterile saline (placebo) injected into the other palm
Number of subjects: 11
Study: 8123390

Group type: EXPERIMENTAL
Intervention: Nitrous oxide exposure for 30, 60, or 120 min with normoventilation or hypoventilation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hypoventilation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Normoventilation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hypoventilation after 1 or 2 h of nitrous oxide exposure
Number of subjects: 36
Study: 3909239

Group type: EXPERIMENTAL
Intervention: 1 Gy 3 times a day to a total of 84 Gy
Number of subjects: 168

Group type: COMPARATOR
Intervention: 2 Gy once a day to a total of 64 Gy
Number of subjects: 168
Study: 30177994

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus standard of care (SOC)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus SOC
Number of subjects: 485

Group type: COMPARATOR
Intervention: SOC alone
Number of subjects: 485
Study: 27010377

Group type: EXPERIMENTAL
Intervention: r‐TMS at frequencies of 5 Hz and 10 Hz for 15 minutes daily for 20 days combined with standard therapy (ST) of 1 hour daily.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard therapy (ST) of 1 hour daily for 20 days.
Number of subjects: 20
Study: 23579578

Group type: EXPERIMENTAL
Intervention: CO2 laser ablative surgery with bowel resection (study group, n = 76)
Number of subjects: 203

Group type: COMPARATOR
Intervention: CO2 laser ablative surgery without bowel resection (control group, n = 127)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Both groups (study and control)
Number of subjects: 203
Study: 22464340

Group type: EXPERIMENTAL
Intervention: Biological treatment (additional infliximab)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Conventional treatment (additional sulfasalazine and hydroxychloroquine)
Number of subjects: 258
Study: 19589691

Group type: EXPERIMENTAL
Intervention: New digital monitoring protocol for chest tube removal
Number of subjects: 166

Group type: COMPARATOR
Intervention: Traditional protocol using visual and subjective assessment of air leak
Number of subjects: 166
Study: 17991759

Group type: EXPERIMENTAL
Intervention: GLP-1
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 17530097

Group type: EXPERIMENTAL
Intervention: Anti-HSP60 IgG in Group A preoperatively
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Anti-HSP60 IgG in Group A postoperatively
Number of subjects: 45

Group type: COMPARATOR
Intervention: Anti-HSP60 IgG in Group B preoperatively
Number of subjects: 45

Group type: COMPARATOR
Intervention: Anti-HSP60 IgG in Group B postoperatively
Number of subjects: 45
Study: 14736626

Group type: EXPERIMENTAL
Intervention: Face-to-face delivered treatment
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Booklet delivered treatment
Number of subjects: 66

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 66
Study: 11039470

Group type: EXPERIMENTAL
Intervention: Biologic porcine secretin (1 CU/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Synthetic porcine secretin (0.2 microg/kg)
Number of subjects: 12
Study: 9187783

Group type: EXPERIMENTAL
Intervention: 10 micrograms.kg‐1.min‐1 propofol
Number of subjects: 41

Group type: COMPARATOR
Intervention: 0.25 microgram.kg‐1.min‐1 midazolam
Number of subjects: 41
Study: 1343377

Group type: EXPERIMENTAL
Intervention: Silymarin (280 mg/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Silymarin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Patients who abstained from alcohol
Number of subjects: 72
Study: 3905343

Group type: EXPERIMENTAL
Intervention: 5 mg/ml anhydrous theophylline dissolved in 20% pure alcohol, loading dose of 5 mg/kg and then 1.25 mg/kg every 6 h
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 31370751

Group type: EXPERIMENTAL
Intervention: 3% 2‐chloroprocaine (group C, n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 2% lidocaine (group L, n = 40)
Number of subjects: 80
Study: 25803602

Group type: EXPERIMENTAL
Intervention: Singing an educational song
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (did not sing the song)
Number of subjects: 18
Study: 22684154

Group type: EXPERIMENTAL
Intervention: Minimally-invasive surfactant therapy (MIST)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 61
Study: 21675494

Group type: EXPERIMENTAL
Intervention: Doxepin cream 5%
Number of subjects: 75

Group type: COMPARATOR
Intervention: Betamethasone cream 0.1%
Number of subjects: 75
Study: 19704057

Group type: EXPERIMENTAL
Intervention: Octreotide LAR 30 mg intramuscularly in monthly intervals
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Octreotide LAR
Number of subjects: 85
Study: 16439720

Group type: EXPERIMENTAL
Intervention: Heliox28 (72% He/28% O2)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Heliox21 (79% He/21% O2)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Oxygen28 (72% N2/28% O2)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Medical air (79% N2/21% O2)
Number of subjects: 82
Study: 12630026

Group type: EXPERIMENTAL
Intervention: High dose hepatitis B virus vaccination (40 mcg) with a shortened immunization schedule
Number of subjects: 138
Study: 11203962

Group type: EXPERIMENTAL
Intervention: SureFil and Prime & Bond NT
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SureFil and PQ1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SureFil, PermaFlow, and PQ1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Heliomolar and Syntac Single‐Component
Number of subjects: 60
Study: 9359543

Group type: EXPERIMENTAL
Intervention: Dual coil transvenous lead
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Unipolar configuration (distal right ventricular coil and pectoral pulse generator shell)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Triad configuration (all 3 components)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Triad configuration
Number of subjects: 21

Group type: COMPARATOR
Intervention: Unipolar configuration
Number of subjects: 21
Study: 7694528

Group type: EXPERIMENTAL
Intervention: Desflurane anesthesia with epinephrine doses of 7.0-13.0 micrograms/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia with epinephrine doses of 7.0-13.0 micrograms/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both anesthetic groups with epinephrine doses less than 7.0 micrograms/kg
Number of subjects: 36
Study: 4053529

Group type: EXPERIMENTAL
Intervention: Sodium diclofenac (100 mg tablets of slow-release diclofenac)
Number of subjects: 25
Study: 29861177

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 0
Study: 30295803

Group type: EXPERIMENTAL
Intervention: Text-messaging adherence support
Number of subjects: 181

Group type: COMPARATOR
Intervention: Standard of care for PrEP adherence
Number of subjects: 181
Study: 27575673

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Inhalation aromatherapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 25322540

Group type: EXPERIMENTAL
Intervention: Membrane sweeping (Sweeping Group)
Number of subjects: 140

Group type: COMPARATOR
Intervention: No membrane sweeping (Control Group)
Number of subjects: 140
Study: 21993599

Group type: EXPERIMENTAL
Intervention: Successful ablation
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Decrease in NT‐pro‐BNP >25% from baseline
Number of subjects: 38
Study: 19885712

Group type: EXPERIMENTAL
Intervention: Alumina matrix composite femoral heads articulating on alumina liners
Number of subjects: 65

Group type: COMPARATOR
Intervention: Zirconia femoral heads on polyethylene liners
Number of subjects: 65
Study: 17919556

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 382

Group type: COMPARATOR
Intervention: Bayesian network prediction
Number of subjects: 382
Study: 16195897

Group type: EXPERIMENTAL
Intervention: PMR plus medical management
Number of subjects: 73

Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 73
Study: 11135723

Group type: EXPERIMENTAL
Intervention: Sustained-release hydromorphone (8, 16, and 32 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Immediate-release hydromorphone (8 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9701300

Group type: EXPERIMENTAL
Intervention: Instructor-taught CPR class
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Instructor-taught CPR class followed by a social support intervention
Number of subjects: 480

Group type: COMPARATOR
Intervention: Self-training video module
Number of subjects: 480
Study: 7857346

Group type: EXPERIMENTAL
Intervention: pidotimod 50 mg, 100 mg, 200 mg twice a day
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: pidotimod (any dosage)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: pidotimod 400 mg/day
Number of subjects: 43

Group type: COMPARATOR
Intervention: physiological saline
Number of subjects: 43
Study: 2706957

Group type: EXPERIMENTAL
Intervention: 10 widely used surfactants and 1 solubilizer applied in aqueous solutions of 12.5 millimoles/l for 45 min twice daily for 3 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TEWL measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual scoring system
Number of subjects: 0
Study: 802649

Group type: EXPERIMENTAL
Intervention: alpha-methyldopa
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: guanethidine
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: clonidine
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: reserpine
Number of subjects: 41
Study: 29748900

Group type: EXPERIMENTAL
Intervention: eHealth Familias Unidas
Number of subjects: 230

Group type: COMPARATOR
Intervention: Prevention as usual
Number of subjects: 230
Study: 27145774

Group type: EXPERIMENTAL
Intervention: Bicruciate-retaining total knee arthroplasty (BCR group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Medial unicompartmental knee arthroplasty (UKA group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Posterior stabilized total knee arthroplasty (PS group)
Number of subjects: 60
Study: 26411223

Group type: EXPERIMENTAL
Intervention: Ultrasound monitored TCRS
Number of subjects: 126

Group type: COMPARATOR
Intervention: Laparoscope monitored TCRS
Number of subjects: 126
Study: 23041968

Group type: EXPERIMENTAL
Intervention: Cryotherapy followed by 30 min of exercise
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cryotherapy followed by 30 min of rest
Number of subjects: 12
Study: 21304253

Group type: EXPERIMENTAL
Intervention: Morning medication (50 mg of naftopidil once a day after breakfast for 8 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Evening medication (50 mg of naftopidil once a day after supper for 8 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Morning medication (50 mg of naftopidil)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Evening medication (50 mg of naftopidil)
Number of subjects: 100
Study: 19736473

Group type: COMPARATOR
Intervention: Folic acid (FA), 5 mg/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Folic acid (FA), 5 mg/day + vitamin B12, 1 mg/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Folic acid (FA), 15 mg/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Folic acid (FA), 15 mg/day + vitamin B12, 1 mg/day
Number of subjects: 36
Study: 17009077

Group type: EXPERIMENTAL
Intervention: Losartan (50 to 100 mg once daily)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 15231472

Group type: EXPERIMENTAL
Intervention: Bovine heart model (BHM) and 2D anatomic pictures of human hearts (Group 2)
Number of subjects: 35

Group type: COMPARATOR
Intervention: 2D anatomic pictures of human hearts (Group 1)
Number of subjects: 35
Study: 11106014

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-thymol varnish application every 3 months
Number of subjects: 29

Group type: COMPARATOR
Intervention: Fluoride gel only (Control)
Number of subjects: 29
Study: 9645783

Group type: EXPERIMENTAL
Intervention: Computer-assisted learning (CAL)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Lecture and feedback seminar (LFS)
Number of subjects: 82
Study: 9508950

Group type: EXPERIMENTAL
Intervention: Artificial saliva substitute
Number of subjects: 25
Study: 3335295

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate, amoxicillin, and the combination of colloidal bismuth subcitrate and amoxicillin
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Amoxicillin monotherapy
Number of subjects: 337

Group type: COMPARATOR
Intervention: C. pyloridis positive culture
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Initial eradication of C. pyloridis
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Successful eradication of C. pyloridis
Number of subjects: 337
Study: 31805983

Group type: EXPERIMENTAL
Intervention: Modification of the style of the participant information leaflet (PIL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delaying provision of the full PIL until the potential participant attended the trial clinic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modification of the style of the PIL
Number of subjects: 0
Study: 28302406

Group type: EXPERIMENTAL
Intervention: Microalgae oil (2.1 g DHA/d)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sunflower oil (placebo)
Number of subjects: 38
Study: 26782853

Group type: EXPERIMENTAL
Intervention: 800 IU/d of vitamin D3
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 2000 IU/d of vitamin D3
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 4000 IU/d of vitamin D3
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 50000 IU/wk of vitamin D3
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Total and free 25(OH)D
Number of subjects: 81
Study: 24821095

Group type: EXPERIMENTAL
Intervention: Strengthening Families Program plus Life Skills Training (LST)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Life Skills Training (LST) only
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 36
Study: 21369788

Group type: EXPERIMENTAL
Intervention: Increased sunlight exposure (additional 30‐40 min/day in the early morning) with calcium supplementation (600 mg/day)
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Increased sunlight exposure (additional 30‐40 min/day in the early morning) without calcium supplementation
Number of subjects: 602

Group type: COMPARATOR
Intervention: Control group (neither increased sunlight exposure nor calcium supplementation)
Number of subjects: 602